Dagenais GR, et al. - Researchers investigated the impact of insulin or omega-3 supplements on the incidence and progression of peripheral artery disease (PAD) in patients with dysglycemia via performing the ORIGIN trial. Participants with dysglycemia and cardiovascular risk factors were randomized to titrated insulin glargine vs standard care and to either 1 g of omega-3 per day or placebo. Allocation to insulin glargine vs standard care had a neutral effect on the composite of PAD incidence and progression over a 6.2-year follow-up period. Results were similar among participants allocated to the omega-3 and placebo groups for PAD incidence and progression. According to findings, neither insulin glargine nor omega-3 affected PAD incidence or progression.